These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25272224)

  • 1. Circulating RNA molecules as biomarkers in liver disease.
    Enache LS; Enache EL; Ramière C; Diaz O; Bancu L; Sin A; André P
    Int J Mol Sci; 2014 Sep; 15(10):17644-66. PubMed ID: 25272224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human.
    Musaddaq G; Shahzad N; Ashraf MA; Arshad MI
    Biomarkers; 2019 Mar; 24(2):103-109. PubMed ID: 30252499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease.
    Pant K; Venugopal SK
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):370-377. PubMed ID: 27956256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal miRNAs as biomarkers in the diagnosis of liver disease.
    Wang S; Wang JQ; Lv XW
    Biomark Med; 2017 May; 11(6):491-501. PubMed ID: 28598214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating RNA: looking at the liver through a frosted glass.
    Falcon-Perez JM; Royo F
    Biomarkers; 2015; 20(6-7):339-54. PubMed ID: 26616145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases.
    Shabangu CS; Huang JF; Hsiao HH; Yu ML; Chuang WL; Wang SC
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.
    Povero D; Eguchi A; Li H; Johnson CD; Papouchado BG; Wree A; Messer K; Feldstein AE
    PLoS One; 2014; 9(12):e113651. PubMed ID: 25470250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
    Pavlik L; Regev A; Ardayfio PA; Chalasani NP
    Drug Saf; 2019 Jun; 42(6):701-711. PubMed ID: 30762163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as biomarkers for clinical studies.
    Pogribny IP
    Exp Biol Med (Maywood); 2018 Feb; 243(3):283-290. PubMed ID: 28914096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs in liver disease.
    Wang XW; Heegaard NH; Orum H
    Gastroenterology; 2012 Jun; 142(7):1431-43. PubMed ID: 22504185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases: Implications for Organ Allo- and Xeno-Transplantation.
    Zhou M; Hara H; Dai Y; Mou L; Cooper DK; Wu C; Cai Z
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27490531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs and liver disease.
    Otsuka M; Kishikawa T; Yoshikawa T; Yamagami M; Ohno M; Takata A; Shibata C; Ishibashi R; Koike K
    J Hum Genet; 2017 Jan; 62(1):75-80. PubMed ID: 27225852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
    Kwo PY; Cohen SM; Lim JK
    Am J Gastroenterol; 2017 Jan; 112(1):18-35. PubMed ID: 27995906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
    Amacher DE
    Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury.
    Yamaura Y; Tatsumi N; Takagi S; Tokumitsu S; Fukami T; Tajiri K; Minemura M; Yokoi T; Nakajima M
    Clin Biochem; 2017 Dec; 50(18):1034-1039. PubMed ID: 28823616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.
    Clarke JD; Sharapova T; Lake AD; Blomme E; Maher J; Cherrington NJ
    J Appl Toxicol; 2014 Jun; 34(6):726-32. PubMed ID: 24217942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
    Ajmera V; Perito ER; Bass NM; Terrault NA; Yates KP; Gill R; Loomba R; Diehl AM; Aouizerat BE;
    Hepatology; 2017 Jan; 65(1):65-77. PubMed ID: 27532276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.